Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial

START trial team

Research output: Contribution to journalArticlepeer-review

318 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial'. Together they form a unique fingerprint.

Medicine & Life Sciences